Genomic Testing | Clinical

January 12, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.

January 01, 2021

During a debate at the 27th Annual Prostate Cancer Foundation Virtual Scientific Retreat, Daniel Spratt, MD, debated Daniel Lin, MD, on the subject of genomic classifiers in prostate cancer.

November 17, 2020

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

November 17, 2020

The Access to Comprehensive Genomic Profiling Coalition has been formed by 7 leading diagnostic companies and laboratory providers across the United States to advocate for appropriate broad health insurance coverage of comprehensive genomic profiling for patients with advanced-stage cancer.

July 21, 2020

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

July 10, 2020

Jennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.

June 01, 2020

Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.

March 17, 2020

In an interview with Targeted Oncology, Carl Morrison, MD, DVM, senior vice president Roswell Park Comprehensive Cancer Center, discussed the rationale for evaluating the Ion Torrent-based approach to predicting response to immunotherapy. He highlighted the importance of this in the clinical setting and advances are necessary to further validate this as a biomarker of response.

March 11, 2020

Microsatellite instability has been an FDA-indicated biomarker for immunotherapy since 2017, when the PD-1 inhibitor pembrolizumab was approved for patients with solid tumors found to be mismatch repair deficient or MSI high. Other approvals since then, such as for the combination of ipilimumab and nivolumab in patients with MSI-H/dMMR metastatic colorectal can­cer, have established the relevance of cancer thera­pies for tumors with this biomarker specifically rather than tumor histology alone.

March 10, 2020

In an interview with Targeted Oncology, Whitney Ducaine, MGC, CGC, CN-BM, discussed the evolution of genetic testing in oncology. She highlighted the importance of having conversations with genetic counselors to help inform the patient on their familial risks as well to help inform treatment decisions.